Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can heavy water reveal how the liver makes fat?

NCT ID NCT07742423

Knowledge-focused Sponsor: KU Leuven Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study tests a new analytical method for measuring how the liver produces fat (de novo lipogenesis) using heavy water, a safe, non-radioactive tracer. Ten healthy adults aged 18-60 with a normal BMI will drink heavy water for 10 days, and researchers will track its incorporation into fat molecules in the blood. The goal is to validate this protocol for future research into metabolic health and conditions like fatty liver disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Deuterium oxide (heavy water), a non-radioactive stable isotope tracer taken orally for 10 days
What this could lead to
If successful, this could provide a reliable, minimally invasive way to measure liver fat production, aiding research into metabolic conditions like fatty liver disease.
What could go wrong
This is a small, early-stage validation study in healthy people, so results may not apply to patients. Heavy water is generally safe but may cause mild dizziness or nausea at high doses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

10 people

The number who actually took part.

Started

Aug 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy male or female individuals. * Age between 18-60 years old with a body mass index (BMI) between 18.5 and 25 kg/m². * Willingness to consume ²H₂O as part of the study protocol. Exclusion Criteria: Participants will be excluded from the study based on self-reported health status if they meet any of the following conditions: * Chronic diseases (e.g., diabetes, MASLD, hypertension, cardiovascular diseases) and/or chronic consumption of medication (e.g., antihypertensive drugs, diabetes medications, lipid-lowering agents, immunomodulatory drugs, or other prescribed medications for long-term management of health conditions). * History of blood donation within the past 3 months. * Vaccination within the past 4 weeks. * Pregnancy or breastfeeding. * Participation in another clinical study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for De novo lipogenesis (DNL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

De novo lipogenesis (DNL) Healthy volunteers (HV) Lipid metabolism Stable isotope tracing

Contacts and locations

Locations

  • KU Leuven/ UZ Leuven

    Leuven, Vlaams-Brabant, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.